Navigation Links
ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders
Date:9/6/2010

treated patients (p=0.000003). Epiretinal membrane is a layer of scar tissue which builds up on the macula, making it more difficult to achieve resolution of VMA without surgical intervention. Epiretinal membrane can be easily identified using Optical Coherence Tomography (OCT).

The MIVI-TRUST program's pooled results also highlighted microplasmin's impressive effect in patients diagnosed with FTMH. In this group, 40.6% of the 106 patients saw closure of their FTMH at 28 days following a single 125micro-g injection of microplasmin without the need for a vitrectomy. This compares with 10.6% of the 47 patients in the placebo group (p= 0.00015). The closure of FTMH also led to microplasmin treated patients experiencing a significant improvement in their visual acuity (VA) compared to baseline.

Prof. Stalmans also presented an analysis of the pooled visual acuity data from the Phase III program. This showed that at the end of the six month study period, 23.7% of the microplasmin treated patients had achieved at least a 10 letter (2 lines) improvement in VA without the need for vitrectomy. This compares to only 11.2% of the patients who received a placebo injection (p=0.0002). Within the microplasmin treated population, 9.7% of patients achieved a 15 letter (3 lines) improvement in their visual acuity without the need for vitrectomy, compared to just 3.7% of the placebo patients (p=0.01). In addition, microplasmin treated patients showed an improved Quality of Life when compared to placebo, based on the VFQ-25 (the National Eye Institute Visual Functioning Questionnaire) results.

The pooled results also confirmed that microplasmin was generally safe and well tolerated. There was no evidence of an increased risk of retinal tear or detachment.

Dr. Patrik De Haes, CEO of ThromboGenics, commented, "The successful completion and reporting of our 652 patient Phase III program with microplasmin in just 20 months demonstrates ThromboGenics' highl
'/>"/>

SOURCE ThromboGenics NV
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
8. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
9. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
10. ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
11. ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... OmniSeq, LLC today announced the addition ... SM Genomic Network.  Recently, OmniSeq officially spun ... announced it was making available a suite of ... to genomic diagnostics that provides actionable results to ... rapidly expanding, multidisciplinary cancer care center that is ...
(Date:8/3/2015)... 3, 2015  Sage Analytics ( www.sageanalytics.com ), the ... potency measurement systems, announced its sponsorship of the California ... A limited number of tickets are available for groups ... great cause while enjoying an open bar, buffet dinner ... San Francisco Bay at sunset. With the ...
(Date:8/3/2015)... 3, 2015 Ortho Clinical Diagnostics (OCD) today ... Chief Corporate Brand and Communications Officer, effective immediately. As ... Bouryal will lead the company,s worldwide corporate brand and ... to an independent company by adding sites in countries ... Chief Executive Officer Dr. Martin Madaus . ...
Breaking Medicine Technology:OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 2OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 3Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2Ortho Clinical Diagnostics Appoints Kristie Bouryal Chief Corporate Brand and Communications Officer 2
... CHICAGO, Nov. 10 Advanced Life Sciences Holdings, ... engaged in the discovery, development and commercialization of novel ... respiratory diseases, today announced its financial results for the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO ) , The net loss ...
... NEW YORK, Nov. 10 Reportlinker.com announces ... available in its catalogue. , The ... Market Outlook , http://www.reportlinker.com/p0158356/The-Global-Drug-Delivery-Market-Research-Trends-and-Market-Outlook.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire ... drug delivery industry has in recent years ...
Cached Medicine Technology:Advanced Life Sciences Announces Third Quarter 2009 Financial Results 2Advanced Life Sciences Announces Third Quarter 2009 Financial Results 3Advanced Life Sciences Announces Third Quarter 2009 Financial Results 4Advanced Life Sciences Announces Third Quarter 2009 Financial Results 5Advanced Life Sciences Announces Third Quarter 2009 Financial Results 6Advanced Life Sciences Announces Third Quarter 2009 Financial Results 7Advanced Life Sciences Announces Third Quarter 2009 Financial Results 8Advanced Life Sciences Announces Third Quarter 2009 Financial Results 9Advanced Life Sciences Announces Third Quarter 2009 Financial Results 10Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 2Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 3Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 4Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 5Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 6Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 7Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 8Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 9Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 10Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 11
(Date:8/3/2015)... ... August 03, 2015 , ... They know every second counts. And when it ... offers some of the best care in the nation. For the past two months, ... average blood clot removal time in the country. During the months of June and ...
(Date:8/3/2015)... ... , ... Bayer has agreed to pay $56.9 million to set up a ... to have suffered an arterial blood clot including stroke and heart attack. The litigation ... has been ongoing for well-over five years. In 2009, lawsuits filed against Bayer involving ...
(Date:8/3/2015)... ... 03, 2015 , ... Kantor & Kantor, LLP announced today ... client Rebecca Hamsher, deciding that in accordance with ERISA ( Employee Retirement Income ... treatment for bulimia, depression and other mental health problems. , According to the ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb B2B Awards celebrate ... BESLER Consulting's campaign for the launch of their Readmissions Analytics product was selected ...
(Date:8/3/2015)... ... August 03, 2015 , ... Pitt Researchers to Monitor ... of Pittsburgh School of Medicine are leading a five-year, $5 million initiative to ... , A cooperative agreement awarded by the U.S. Agency for International Development ...
Breaking Medicine News(10 mins):Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4
... 6 Mergent, Inc., administrator for the,Healthshares(TM) Indexes, ... Exchange Traded Funds, today announced the following,changes with ... May 9, 2008:,Masimo Corporation (Nasdaq: MASI ) ... in the HealthShares(TM) Composite Index, Quest,Diagnostics Inc (NYSE: ...
... Traffic Reached Record Levels of 51.9 Million Unique Monthly Users and ... ... Health Corp. (Nasdaq:,WBMD) today announced financial results for the three months ... quarter, as,WebMD continued to consolidate its position as the leading source ...
... the annual shareholders,meeting of Sigma-Aldrich Corporation (Nasdaq: SIAL ... re-elected: David R. Harvey, W. Lee,McCollum, Jai P. Nagarkatti, ... R. G. Sear, D. Dean Spatz and Barrett A. ... of Medtronic, Inc., was,elected to her first term as ...
... deals another blow to homocysteine theory , , TUESDAY, May ... supplements aimed at reducing blood levels of the amino ... and stroke, a long-term study found. , It,s the ... lowering homocysteine levels could reduce the incidence of cardiovascular ...
... Healthcare Workers Demonstrate to Protect Their Voice & Vote ... The battle,over the direction of the Service Employees International ... of hearings was held to,determine the fate of more ... Workers -- West (UHW). UHW represents 150,000,caregivers in hospitals, ...
... Epitomics, Inc. announced,today that its Hangzhou subsidiary has ... of its novel line of rabbit monoclonal,antibodies. "This ... quality management and ultimately the finest quality,antibodies available ... Yu,President and CEO of Epitomics, Inc., "ISO ...
Cached Medicine News:Health News:Mergent, Inc. Announces Changes to the HealthShares(TM) Composite, Enabling Technologies, Autoimmune-Inflammation, Cancer, Cardiology and Neuroscience Indexes 2Health News:Mergent, Inc. Announces Changes to the HealthShares(TM) Composite, Enabling Technologies, Autoimmune-Inflammation, Cancer, Cardiology and Neuroscience Indexes 3Health News:Mergent, Inc. Announces Changes to the HealthShares(TM) Composite, Enabling Technologies, Autoimmune-Inflammation, Cancer, Cardiology and Neuroscience Indexes 4Health News:WebMD Announces First Quarter Financial Results 2Health News:WebMD Announces First Quarter Financial Results 3Health News:WebMD Announces First Quarter Financial Results 4Health News:WebMD Announces First Quarter Financial Results 5Health News:WebMD Announces First Quarter Financial Results 6Health News:WebMD Announces First Quarter Financial Results 7Health News:WebMD Announces First Quarter Financial Results 8Health News:WebMD Announces First Quarter Financial Results 9Health News:WebMD Announces First Quarter Financial Results 10Health News:WebMD Announces First Quarter Financial Results 11Health News:WebMD Announces First Quarter Financial Results 12Health News:WebMD Announces First Quarter Financial Results 13Health News:WebMD Announces First Quarter Financial Results 14Health News:WebMD Announces First Quarter Financial Results 15Health News:WebMD Announces First Quarter Financial Results 16Health News:WebMD Announces First Quarter Financial Results 17Health News:WebMD Announces First Quarter Financial Results 18Health News:WebMD Announces First Quarter Financial Results 19Health News:WebMD Announces First Quarter Financial Results 20Health News:Sigma-Aldrich Shareholders Elect Directors and Ratify Auditor; Directors Declare Quarterly Dividend 2Health News:Folic Acid Doesn't Help the Heart 2Health News:SEIU Retaliates Against California Caregivers & Democratic Reform Movement 2Health News:Epitomics receives ISO 9001 certification for the production of Rabbit Monoclonal Antibodies. 2
Instrument necessary for insertion of Ritleng Bicanaliculus systems and of Self-Threading Monoka systems....
... This unique system uses prolene as thread-guide ... intubation. The hollow Ritleng Probe is inserted ... prolene thread-guide is fed through it. The ... thread to pull the silicone tubing in ...
... system uses prolene as thread-guide reducing time ... hollow Ritleng Probe is inserted into the ... is fed through it. The probe is ... pull the silicone tubing in place. Newly ...
For Canalicular Stenosis in Infants. Medical grade silicone. Note: Can also be used in DCR because of its high flexibility. Probe entirely embedded in silicone tubing (non-traumatic). Box of 3, steri...
Medicine Products: